Log In
BCIQ
Print this Print this
 

Luxiq ViaFoam

Also known as: betamethasone valerate

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionFoam formulation of 0.12% betamethasone valerate
Molecular Target Glucocorticoid receptor (GCCR)
Mechanism of ActionGlucocorticoid receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationPsoriasis
Indication DetailsTreat plaque-type psoriasis; Treat scalp psoriasis
Regulatory Designation
PartnerMylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$50.1M

$50.1M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/18/2016

$50.1M

$50.1M

0

06/17/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today